Differential effect of antiallergic drugs on IgE-mediated cutaneous reaction in passively sensitized mice

Pharmacology

Volumn 60, Issue 2, 2000, Pages 97-104

  Satoh, Taku ^a   Tahara, Eiichi ^a   Yamada, Tomohiro ^a   Watanabe, Chie ^a   Itoh, Takashi ^a   Terasawa, Katsutoshi ^a   Nagai, Hiroichi ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antiallergic agents; IgE mediated cutaneous reaction; Very late phase response

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; ANTIALLERGIC AGENT; AZELASTINE; CYCLOSPORIN A; DIPHENHYDRAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; ISRAPAFANT; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; PRANLUKAST; PREDNISOLONE; TACROLIMUS; TERFENADINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EOSINOPHIL; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN MANIFESTATION;

EID: 0033963296     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028353     Document Type: Article

References (30)

1. Katayama I, Tanei R, Yokozcki H, Nishioka K, Dohi Y: Induction of eczematous skin reaction in experimentally induced hyperplastic skin of Balb/C mice by monoclonal anti-DNP IgE antibody: Possible implications for skin lesion formation in atopic dermatitis. Int Arch Allergy Immunol 1990;93:148-154.
2. Nagai H, Sakurai T, Inagaki N, Mori H: An immunopharmacological study of the biphasic allergic skin reaction in mice. Biol Pharm Bull 1995;18:239-245.
3. Tahara E, Satoh T, Watanabe C, Shimada Y, Itoh T, Nagai H, Terasawa K, Saiki I: A third-phase cutaneous response (very-late-phase response; vLPR) after elicitation with DNFB in passively or actively sensitized mice. Allergol Int 48: in press.
4. Inagaki N, Tsunematsu M, Sakurai T, Matsuo A, Nagai H: Effect of prednisolone on IgE-dependent biphasic cutaneous reaction in BALB/c mice. Gen Pharmacol 1997;28:93-97.
5. Taniguchi K, Masuda Y, Takanaka K: Action sites of antiallergic drugs on human neutrophils. Jpn J Pharmacol 1990;52:101-108.
6. Obata T, Nambu F, Kitagawa T, Terashima H, Toda M, Okegawa T, Kawasaki A: ONO-1078: An antagonist of leukotrienes. Adv Prostaglandin Thromboxane Leukotrienes Res 1987;17A: 540-543.
7. 4 antagonists. Adv Prostaglandin Thromboxane Leukotrienes Res 1991; 21A:411-414.
8. Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T: Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF). II. Interactions with PAF and benzodiazepine receptors. Prostaglandins 1990;40:571-583.
9. Yamaya H, Basaki Y, Togawa M, Kojima M, Kiniwa M, Matsuura N: Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents. Life Sci 1995;56: 1647-1654.
10. Nagai H, Sakurai T, Abe T, Matsuo A, Musoh K, Tsunematsu M, Inagaki N: TNF-alpha participates in an IgE-mediated cutaneous reaction in mast cell deficient, WBB6F1-W/Wv mice. Inflamm Res 1996:45:136-140.
11. Sakurai T, Inagaki N, Nagai H: The effect of anti-tumor necrosis factor (TNF)-alpha monoclonal antibody on allergic cutaneous late phase reaction in mice. Life Sci 1994;54:PL291-295.
12. Hoshino M, Nakamura Y: The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int Arch Allergy Immunol 1997;114:285-292.
13. Gary RK Jr, Woodward DF, Nieves AL, Williams LS, Gleason JG, Wasserman MA: Characerization of the conjunctival vasopermeability response to leukotrienes and their involvement in immediate hypersensitivity. Invest Ophthalmol Vis Sci 1988;29:119-126.
14. Dahlen SE, Hedqvist P, Hammarstorm B, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. Nature 1980;288: 484-486.
15. Nakagawa N, Obata T, Kobayashi T, Okada Y, Nambu F, Terawaki T, Furuya T, Muryobayashi K, Sawada VI, Aishita H: Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma. EurJ Pharmacol 1993;235:211-219.
16. 4. Opthalmic Res 1989;21:297-302.
17. 4 antagonist on eosinophil infiltration in cutaneous and gut late phase response on BALB/C mice sensitized with ovalbumin. Arerugi 1997; 46:42-48.
18. 4: A mediator of vascular permeability. Br J Pharmacol 1981; 72:483-486.
19. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB: Platelet-activating factor: A potent chemotactic and chemokinetic factor for human cosino-phils. J Clin Invest 1986;78:1701-1706.
20. McMurtry IF, Morris KG: Platelet-activating factor causes pulmonary vasodilation in the rat. Am Rev Respir Dis 1986;134:757-762.
21. Chan-Yeung M, Lam S, Chan H, Tse KS, Salari H: The release of platelet-activting factor into plasma during allergen-induced bronchoconstriction. J Allergy Clin Immunol 1991;87: 667-673.
22. Sano H, Nakagawa N, Nakajima H, Yoshida S, Iwamoto I: Role of vascular cell adhesion molecule-1 and platelet-activating factor in selective eosinophil migration across vascular endothelial cells. Int Arch Allergy Immunol 1995;107: 533-540.
23. Kroegel C, Yukawa T, Dent G, Venge P, Chung KF, Barnes PJ: Stimulation of degranulation from human eosinophils by platelet-activating factor. J Immunol 1989;142:3518-3526.
24. Qu XF, Hayashi M, Yamaki K, Oh-ishi S: Assessment of vascular permeability increase in the mouse by dye leakage during paw edema. Jpn J Pharmacol 1990;52:500-503.
25. Qu XF, Yamaki K, Oh-ishi S: Vascular permeability increase in the mouse paw during the passive anaphylaxis reaction. Jpn J Pharmacol 1991;57:255-257,
26. Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Matsuura M, Kawakami Y, Terasawa M: Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs. Inflamm Res 1997;46:147-153.
27. Koda A, Yanagihara Y, Matsuura N: IPD-1151T: A prototype drug for IgE antibody synthesis modulation. Agents Actions Suppl 1991; 34:369-378.
28. Horan RF, Schneider LC, Shelter AL: Allergicskin disorders and mastocytosis. JAMA 1992; 268:2858-2868.
29. Andersson J, Nagy S, Groth CG, Andersson U: Effects of FK506 and cyclosporin A on cytokine production studied in vitro a single-cell level. Immunology 1992;75:136-142.
30. Mori A, Suko M, Nishizaki Y, Kaminuma O, Kobayashi S, Matsuzaki G, Yamamoto K, Ito K, Tsuruoka N, Okudaira H: IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol 1995;7:449-457.